Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Exclusion Criteria

• •Non-epithelial tumors
• •Ovarian tumors with low malignant potential (borderline tumors)
• •History of other malignancy of prognostic relevance within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma, or tumors with a negligible risk for metastasis or death, such as adequately controlled basal-cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ of the breast
• •Previous treatment with more than 2 chemotherapy regimens
• •Any prior radiotherapy to the pelvis or abdomen
• •History or evidence on physical/neurological examination of central nervous system disease unrelated to cancer (uncontrolled seizures), unless adequately treated with standard medical therapy
• •Pre-existing peripheral neuropathy \>/= common toxicity criteria (CTC) grade 2 (applicable for paclitaxel cohort only)
• •Inadequate organ function
• •Uncontrolled hypertension or clinically significant cardiovascular disease
• •Current known infection with human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV), or hepatitis C virus (HCV)
• •Current chronic daily treatment with corticosteroids (\>/= 10 mg per day of methylprednisolone or equivalent), excluding inhaled steroids
• •History of receiving any investigational treatment within 28 days prior to first study drug administration
• •For Part 2 of the trial: prior enrollment into Part 1 of the trial
• •Concurrent participation in any therapeutic clinical trial